Cronos Group Inc vs PubMatic Inc — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.11B), while PubMatic Inc trades at $17.52 (market cap $808.97M). The key difference: Cronos Group Inc is the larger of the two by market cap, and PubMatic Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| CRON | PUBM | |
|---|---|---|
Market Cap | $1.11B | $808.97M |
Sector | Health | Technology |
52-Week High | $3.27 | $17.78 |
52-Week Low | $2.30 | $6.28 |
Enterprise Value | $310.67M | $712.10M |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
PUBM's stock surged 31.9% to $17.78, reflecting strong investor optimism following a Q2 2026 earnings beat with 10.5% revenue growth and improved profitability in mobile app and CTV segments. Technical indicators show a bullish trend with support at $17 and resistance at $18, though RSI levels suggest overbought conditions. The company maintains a robust balance sheet with $120M in cash and positive operating cash flow of $81.06M in 2025, despite a net loss of -$14.46M. Recent leadership changes, including the appointment of a new Global Chief Revenue Officer, aim to accelerate growth amid AI-driven advertising transformations.
The outlook for PUBM is cautiously optimistic, with a consensus price target of $21.50 offering 21% upside potential. Key opportunities include double-digit revenue growth in high-margin segments and AI product adoption, but risks persist from competitive pressures, profitability challenges, and reliance on digital advertising cyclicality. Investors should weigh the strong analyst buy ratings against elevated valuation multiples and execution risks in a dynamic market.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →